Coronavirus: NAFDAC approves Chloroquine production for clinical trial

<!– Prof. Mojisola Adeyeye, Director-General of NAFDAC –>

Prof. Mojisola Adeyeye, Director-General of NAFDAC

The National Agency for Food and Drug Administration and Control (NAFDAC) has approved the production of Chloroquine for clinical trials in tackling the deadly Coronavirus.

Prof. Mojisola Adeyeye, agency’s Director-General, who spoke in Lagos on Friday, stated that NAFDAC was not approving Chloroquine for the treatment of COVID-19 but for clinical trials to find treatment for the virus.

She said in the case of Chloroquine, it had been demonstrated in the literature and with clinical research which is still ongoing, that Chloroquine is superior to the Placebo.

“NAFDAC is not approving Chloroquine as a product that can be used for Coronavirus because there is no submission to us for registration but because it is under clinical trials, NAFDAC approves medicines meant for clinical trials.

“Therefore the medicine is being approved just for the clinical trials,” Adeyeye said.

According to Channels TV, she, therefore, called on experts and researchers that were interested in doing a clinical trial on Chloroquine to approach approved outlets, adding that a drug company had been given an approval to produce chloroquine in batches.

“Right now, we have asked one company to make a batch of Chloroquine for the purpose of clinical trial,” Adeyeye added.

T

<!–

–>